Italian consensus recommendations for the biomarker-based etiological diagnosis in MCI patients.
Biomarkers support the etiological diagnosis of neurocognitive disorders in vivo. Incomplete evidence is available to drive clinical decisions; available diagnostic algorithms are generic and poorly helpful in clinical practice. We aim to develop a biomarker-based diagnostic algorithm for MCI patients, leveraging on knowledge from recognized national experts. With a Delphi procedure, experienced clinicians making variable use of biomarkers in clinical practice and representing five Italian Scientific Societies (Neurology: SINDEM; Neuroradiology: AINR; Biochemistry: SIBioC; Psychogeriatrics: AIP; Nuclear Medicine: AIMN) defined theoretical framework, relevant literature, the diagnostic issues to be addressed, and the diagnostic algorithm. N-1 majority defined consensus achievement. Panelists chose the 2011 NIA-AA diagnostic criteria as the reference theoretical framework and defined the algorithm in 7 Delphi rounds. The algorithm includes: baseline clinical and cognitive assessment, blood examination, and MRI with exclusionary and inclusionary role; DaT-SPECT (if no/unclear parkinsonism) or 123 I-MIBG cardiac scintigraphy for suspected dementia with Lewy bodies with clear parkinsonism [R-VII, 3-1(1)]; FDG-PET for suspected Frontotemporal Lobar Degeneration and low diagnostic confidence of AD [R-VII,4-0 (1 abstained)]; CSF for suspected Alzheimer's disease (AD) [Round-IV, votes:4-1-0]; amyloid-PET if CSF was not possible/accepted [R-V,4-1] or inconclusive [R-VI,5-0]. These consensus recommendations can guide clinicians in the biomarker-based etiological diagnosis of MCI, while guidelines cannot be defined with evidence-to-decision procedures due to incomplete evidence.